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We identified a standard core set of patient-reported symptoms and health-related 
quality-of-life (HRQOL) domains to be assessed in head and neck (H&N) cancer clini-
cal trials. The core symptom and HRQOL domain scores were used to guide recom-
mendations by a working group of experts as part of a National Cancer Institute 
Symptom Management and HRQOL Clinical Trials Planning Meeting. A  PubMed 
search was conducted using the search terms of “health-related quality of life” and 
“head & neck cancer,” limited to publications from January 1, 2000, to December 31, 
2010. Fifty-four articles were used to guide the choice of recommendations. Twenty-
nine symptoms and nine domains were identified, from which 12 H&N-specific core 
symptoms and HRQOL domains were recommended: swallowing, oral pain, skin 
changes, dry mouth, dental health, opening mouth/trismus, taste, excess/thick 
mucous/saliva, shoulder disability/motion, voice/hoarseness, social domain, and 
functional domain. This core set of 12 H&N-specific, patient-reported symptoms and 
HRQOL domains should be assessed in future H&N cancer clinical trials.
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Head and neck (H&N) cancers are in 
close proximity to vital anatomic struc-
tures that are involved in important 
physiological (eg, swallowing, eating) 
and social functions (eg, communication). 
H&N cancer patients often receive mul-
timodality treatment resulting in acute 
and chronic toxicity rates of up to 40% to 
50% (1,2). The National Cancer Institute 
Symptom Management and Quality of 
Life Steering Committee conducted a 
clinical trials planning meeting with the 
goal of identifying a standard core set of 
patient-reported outcomes (PROs) symp-
toms and/or health-related quality-of-life 
(HRQOL) domains to be assed in clini-
cal trials with cancer patients (3). In this 
article, we report the recommended core 
set of symptoms and HRQOL domains 
agreed upon by the H&N working group 
subcommittee that should be assessed 
in future clinical trials for H&N cancer 
patients.
A literature review was conducted to 
guide the committee’s discussion (Figure 1). 
A PubMed (4) search was performed with 
the following search terms: “head & neck 
cancer” and “health-related quality of life.” 
The following search limitations were used 
(by all working groups) to narrow down 
the number of articles: 1) published in the 
period from January 1, 2000, to December 
31, 2010; 2) published in English; 3) human 
subjects; and 4)  patients aged 18  years or 
older. Two hundred sixteen articles were 
found, and 161 were excluded for the fol-
lowing reasons: sample size less than 30, 
primary cancer site was not squamous cell 
carcinoma of the H&N, review article, 
or mean/severity/prevalence scores were 
not reported. Thus, 54 articles (Figure  1; 
Supplementary Table  1, available online) 
were reviewed and used to guide the choice 
of recommended core symptoms and 
HRQOL domains. Mean symptom and 
HRQOL domain scores were abstracted 
from each study. Psychometric properties 
of the PRO measures used in the study and 
variability of clinical factors (eg, cancer site, 
treatment type) were not evaluated.
The H&N working group subcommit-
tee members included experts in the fields 
of H&N radiation oncology (B. Movsas, 
A. Eisbruch, and B. S. Chera), H&N sur-
gery (D. Ridge), medical oncology (B. 
Murphy), and HRQOL (B. Movsas and 
B. A. Murphy) and a patient advocate who 
is an H&N cancer survivor (P. Gavin). 
B. S. Chera was responsible for the lit-
erature search, providing the committee 
with a synopsis of the literature review 
and authorship of session summaries and 
manuscript materials. The expert panel 
had monthly teleconferences between 
February 2011 and August 2012. A  list of 
symptoms and HRQOL domains based on 
the literature and expert review was cre-
ated, and all six committee members com-
pleted a Web-based survey ranking each as 
high, medium, or low priority. Symptoms/
HRQOL domains with more than five or 
six high-priority votes were considered first 
tier, those with three or four high-priority 
votes were considered second tier, and 
those with two or less high-priority votes 
were discarded. A core set of symptoms and 
HRQOL domains were selected from the 
first- and second-tier symptom/domain 
list. Consensus was reached through inter-
nal committee discussions. Symptoms that 
were independently identified by the cross-
cutting working group were labeled as 
cross-cutting (3).
Fifty-four articles guided the com-
mittee’s recommendations (Figure  1; 
Supplementary Table  1, available online). 
The study design was prospective in 15 
studies, and a majority of the remaining 
studies were cross-sectional. The most 
frequently used instrument (Table  1) was 
the European Organization for Research 
and Treatment of Cancer Quality of Life 
Questionniare-30 (EORTC QLQ-C30) 
and its companion H&N module (H&N-
35). Other common instruments included 
the University of Washington Quality of 
Life Questionnaire and the Functional 
Assessment of Cancer Therapy–Head and 
Neck (FACT–HN). For the vast major-
ity of the studies, pre- and post-treatment 
scores for symptoms and HRQOL domains 
returned to baseline values. Also, HRQOL 
was equivalent between H&N cancer survi-
vors and normative cohorts. Only responses 
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to questions for dry mouth and swallowing 
were consistently higher after treatment 
across studies. There were 29 symptoms 
and seven HRQOL domains that were 
commonly assessed in the literature and 
through the voting process and discussion 
at the subcommittee level (expert panel) 
and at the National Cancer Institute clinical 
trials planning meeting; 12 H&N-specific 
core symptoms and HRQOL domains 
were selected: 1)  swallowing, 2)  pain/oral, 
3)  skin changes, 4)  dry mouth, 5)  dental 
health, 6) opening mouth/trismus, 7) taste, 
8)  excess/thick mucous/saliva, 9)  shoul-
der disability/motion, 10)  voice/hoarse-
ness, 11) social domain, and 12) functional 
domain (Supplementary Table  2, avail-
able online). An additional seven cancer 
cross-cutting symptoms were identified: 
1)  anorexia, 2)  pain/general, 3)  nausea/
vomiting, 4) anxiety, 5) dyspnea, 6) fatigue, 
and 7) depression (Supplementary Table 2, 
available online). Of note, the symptom of 
skin changes was not found in the literature 
review but was selected as a core symptom 
based on expert opinion.
The H&N working group identified 
12 H&N cancer–specific symptoms and 
HRQOL domains that are most relevant 
for assessment in H&N clinical trials. In 
addition, we identified seven cross-cutting 
symptoms that should also be evaluated. 
These more general symptoms were also 
independently recommended by the can-
cer cross-cutting working group (3). The 
importance of incorporating PROs in 
clinical trial design is being recognized in 
the H&N oncology research community. 
Cooperative groups are now designing 
clinical studies with PROs as primary and 
secondary objectives/endpoints. However, 
several issues may need to be resolved 
before PROs are effectively used in clinical 
trials to yield practice-changing results.
Since the early 1990s, the major focus 
in H&N cancer has been the intensifica-
tion of nonsurgical treatment with the 
addition of chemotherapy neoadjuvantly 
and concomitantly with radiotherapy. 
This has led to a dramatic escalation of 
the prevalence/severity/duration of acute 
and chronic toxicities with each succes-
sive clinical trial but with relatively small 
incremental improvements in outcomes 
(5). In our quest for finding a cure, toxic-
ity has, at times, taken a back seat. Patient 
perspectives (ie, PROs) should be incorpo-
rated into H&N cancer clinical trials with 
focused hypotheses.
Recently it has been observed that more 
than 50% of oropharyngeal squamous cell 
carcinomas are associated with the human 
papilloma virus, and this patient cohort 
has been observed to be a unique clinical/
biological/epidemiological entity that is 
associated with a markedly better prog-
nosis (6–9). There are several initiatives 
underway with nonsurgical and surgical 
treatments to deintensify therapy with the 
purpose of reducing the toxicity burden on 
patients. This favorable cohort of patients 
may provide an excellent opportunity for 
incorporating PROs into clinical study 
designs.
The ongoing RTOG 1016 phase III 
study is an example of a combined endpoint 
analysis trial that both evaluates survival 
and PROs (10). As compared with radiation 
therapy (RT) alone, cetuximab in conjunc-
tion with RT has been shown to improve 
survival in locally advanced H&N cancer 
while not increasing the rate of grade 3 or 
greater mucositis or dysphagia, late effects, 
or worsening HRQOL (11,12). RTOG 
1016 is evaluating the noninferiority and 
the acute and chronic toxicity burden of 
PubMed (n = 216)
• Search terms: "health-related quality of life" and "head & neck cancer"
• Search limits: human subjects, English language, patients aged ≥18, from past 10 years
Articles reviewed and used 
to guide Head and Neck Core 
Recommendations (n = 54)




• Sample size <30 
• Unable to abstract mean scores, prevalence, severity
Figure 1. Flowchart of the selection process of articles for the literature review. Fifty-four articles were selected for evaluation and review.
Table 1. Health-related quality-of-life instruments used in the literature*





FACT-G & HN 3
Other 17
* These are the most common health-related quality-of-life instruments used in studies obtained from the 
literature review. EORTC QLQ-30/H&N-35 = European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire 30/Head & Neck 35; FACT-G & HN = Functional Assessment of Cancer 
Therapy General and Head and Neck; HADS = Hospital Anxiety and Depression Scale; SF-36 = Short Form 
36; UW-QOL= University of Washington Quality of Life Questionnaire.
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cetuximab vs cisplatin in conjunction with 
RT. In addition to clinician assessments 
of toxicity, RTOG 1016 incorporates rel-
evant PRO measures (eg, Patient-Reported 
Outcomes version of the CTCAE, EORTC 
QLQ-C30/H&N-35).
Another approach for deintensification of 
treatment is to primarily treat with transoral 
laser microsurgery and transoral robotic sur-
gery. The potential benefits of primary tran-
soral laser microsurgery/transoral robotic 
surgery are subsequent reduction in the 
intensity of chemotherapy and RT without 
compromising oncologic outcomes. The 
RTOG and ECOG are currently conducting 
phase II trials that have incorporated PROs 
(RTOG 1221 and ECOG 3311) (13,14).
Our clinical knowledge regard-
ing the trajectory of toxicities is limited. 
Occurrences of toxicities are tradition-
ally divided into several time periods as 
they relate to treatment: acute, subacute, 
and chronic. It is likely that acute/suba-
cute/chronic is a spectrum, and thus this 
arbitrary categorization may limit our 
understanding of treatment-related tox-
icity. Chronic toxicities (ie, xerostomia, 
dysphagia, dental health) likely begin dur-
ing treatment, although their impact on 
patient HRQOL during the acute treat-
ment phase may be overshadowed by other 
toxicities (ie, oral/pain). Furthermore, the 
impact of a particular toxicity for a patient 
may differ depending upon expectations, 
goals of treatment, and personal values. 
Furthermore, the interdependence of 
symptoms and HRQOL domains has not 
been well studied. For example, swallow-
ing is affected by xerostomia, excess/thick 
mucous/saliva, and direct damage to the 
swallowing muscles.
In our literature review, we noted that 
PRO assessments were not performed 
during treatment. Thus, the validity of 
established PRO instruments during the 
acute treatment phase should be studied. 
Table  2 lists several commonly used vali-
dated instruments and denotes whether the 
recommended core symptoms are assessed. 
Of note, the validity of PRO instruments 
is already known to be affected by certain 
Table 2. Selected health-related quality-of-life instruments for assessment of head and neck cancer core symptoms in clinical trials*
Core symptom EORTC QLQ-H&N-35 UW-QOL FACT-HN
Swallowing Have you had problems swallowing 
liquids?
Have you had problems swallowing 
pureed food?
Have you had problems swallowing solid 
food?
Have you choked when swallowing?
I can swallow as well as ever.
I cannot swallow certain solid foods.
I can only swallow liquid food.
I cannot swallow because it “goes down the 
wrong way” and chokes me.
I can swallow naturally and 
easily.
Pain/oral Have you had pain in your mouth? I have no pain.
There is mild pain not needing medication.
I have moderate pain–requires regular 
medication (codeine or nonnarcotic).
I have severe pain controlled only by 
narcotics.
I have severe pain, not controlled by 
medication.
I have pain in my mouth, 
throat, or neck.
Skin changes NA NA NA
Dry mouth Have you had a dry mouth? My saliva is of normal consistency.
I have less saliva than normal, but it is 
enough.
I have too little saliva.
I have no saliva.
My mouth is dry.
Dental health Have you had problems with your teeth? NA NA
Opening mouth/ 
trismus
Have you had problems opening your 
mouth wide?
NA NA
Taste Have you had problems with your sense 
of taste?
I can taste food normally.
I can taste most foods normally.
I can taste some foods.









NA I have no problem with my shoulder.
My shoulder is stiff, but it has not affected 
my activity or strength.
Pain or weakness in my shoulder has caused 
me to change my work.
I cannot work due to problems with my 
shoulder.
NA
* Recommended 10 core head and neck cancer–specific symptoms that are assessed by selected health-related quality-of-life instruments. Functional and social domains 
are assessed in the European Organization for Research and Treatment of Cancer Quality of Life Questionniare-30 (EORTC QLQ-C30) and its companion Head & Neck 
module (H&N-35) and Functional Assessment of Cancer Therapy–Head and Neck (FACT-HN) but not the University of Washington Quality of Life Questionnaire (UW-QOL). 
There are many other validated instruments that may be appropriate. The most frequently used instruments in our literature are presented. NA = not assessed.
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phenomena: response shift, floor/ceiling 
effect, and so on (15,16). The impact of 
these issues with repeated assessment of 
acute toxicities is unknown. In addition, 
most H&N cancer patients experience 
grade 3 or greater toxicity during treat-
ment. A possible issue is the potential diffi-
culty of collecting PRO data from patients 
who are acutely sick from their cancer 
treatments.
The recommended core set of symp-
toms/HRQOL domains (Supplementary 
Table  2, available online) is not meant to 
be all-encompassing. These recommenda-
tions are limited by what could be gleaned 
from the literature. Certainly there could 
be other symptoms and HRQOL domains 
that are important but were not reported/
studied in the literature. Nevertheless, the 
experts on this panel agreed that these 
symptoms and HRQOL domains are 
relevant to most H&N cancer patients 
and should be evaluated in clinical trials. 
Depending on the clinical trial hypothesis, 
assessment of all of the recommended core 
symptoms and HRQOL domains may not 
be necessary, and other relevant symptoms/
HRQOL domains may need to be included. 
Selection of which PROs to assess will also 
depend upon the specific questions being 
asked in the study. This recommended core 
set of PROs will provide a standardized 
framework to allow for uniformity of com-
parison and should serve as a foundation or 
starting point for incorporation of PROs as 
part of routine patient-reported assessment 
in H&N clinical trials.
In addition to the recommended symp-
toms from the cancer cross-cutting group 
(3), these symptoms and HRQOL domains 
should be assessed in H&N cancer clinical 
trials: swallowing, pain/oral, skin changes, 
dry mouth, dental health, opening mouth/
trismus, taste, excess/thick mucous/
saliva, shoulder disability/motion, voice/
hoarseness, social domain, and functional 
domain.
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